Assertio Holdings Inc. is a leading commercial pharmaceutical company that brings differentiated branded prescription products to patients across key therapeutic areas. It maintains a robust portfolio focused on neurology, inflammation, pain management, oncology, and hospital products, including medications such as INDOCIN for treating rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, gouty arthritis, and acute painful shoulder; Sympazan, a benzodiazepine for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome; Otrexup, SPRIX, CAMBIA, and Zipsor; as well as Rolvedon in oncology following strategic business development. The company specializes in acquiring, licensing, and optimizing commercial-stage assets through an acquisition-driven model, emphasizing targeted marketing and lifecycle management to serve patients primarily in the United States. Founded in 1995 and headquartered in Lake Forest, Illinois, Assertio Holdings Inc. plays a vital role in the specialty pharmaceuticals sector by providing established, high-margin products in neuroscience, immunology, and oncology.